Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/98522
標題: 評估鉻離子對於Olanzapine誘導肥胖雌性大鼠的影響
Evaluation of chromium on olanzapine-induced obesity in female rats
作者: 洪義証
Yi-Jheng Hong
關鍵字: olanzapine

肥胖
olanzapine
chromium
obesity
引用: 中文參考書目 網路資源 Health Promotion Administration, M.o.H.a.W. (2018). 【 BMI 測試】│健康九九網站. English bibliography Journal Articles Altschuler, E.L., and Kast, R.E. (2005). Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression. Med Hypotheses 65, 65-67. American Diabetes, A., American Psychiatric, A., American Association of Clinical, E., and North American Association for the Study of, O. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27, 596-601. Anderson, R.A. (1998). Effects of chromium on body composition and weight loss. Nutr Rev 56, 266-270. Arciniegas, D.B. (2015). Psychosis. Continuum (Minneap Minn) 21, 715-736. Barroso, E., Rodriguez-Calvo, R., Serrano-Marco, L., Astudillo, A.M., Balsinde, J., Palomer, X., and Vazquez-Carrera, M. (2011). The PPARbeta/delta activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1alpha-Lipin 1-PPARalpha pathway leading to increased fatty acid oxidation. Endocrinology 152, 1848-1859. Bonnard, C., Durand, A., Vidal, H., and Rieusset, J. (2008). Changes in adiponectin, its receptors and AMPK activity in tissues of diet-induced diabetic mice. Diabetes Metab 34, 52-61. Burkewitz, K., Zhang, Y., and Mair, W.B. (2014). AMPK at the nexus of energetics and aging. Cell Metab 20, 10-25. Chang, S.H., Stoll, C.R., Song, J., Varela, J.E., Eagon, C.J., and Colditz, G.A. (2014). The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg 149, 275-287. Chen, H.Y., Trumbauer, M.E., Chen, A.S., Weingarth, D.T., Adams, J.R., Frazier, E.G., Shen, Z., Marsh, D.J., Feighner, S.D., Guan, X.M., et al. (2004). Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 145, 2607-2612. Chen, W.Y., Chen, C.J., Liu, C.H., and Mao, F.C. (2010). Chromium attenuates high-fat diet-induced nonalcoholic fatty liver disease in KK/HlJ mice. Biochem Biophys Res Commun 397, 459-464. Clodfelder, B.J., Emamaullee, J., Hepburn, D.D., Chakov, N.E., Nettles, H.S., and Vincent, J.B. (2001). The trail of chromium(III) in vivo from the blood to the urine: the roles of transferrin and chromodulin. J Biol Inorg Chem 6, 608-617. Davoodi, N., Kalinichev, M., Korneev, S.A., and Clifton, P.G. (2009). Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine. Psychopharmacology (Berl) 203, 693-702. De Hert, M., Detraux, J., van Winkel, R., Yu, W., and Correll, C.U. (2011). Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8, 114-126. De Hert M., H.L., Wampers M., Van Winkel R., Van Eyck D., Scheen A., et al (2007). Prevalence and incidence rates of metabolic abnormalities and diabetes in a prospective study of patients treated with second-generation antipsychotics. Schizophr Bull, 560. Deng, C., Weston-Green, K., and Huang, X.F. (2010). The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuropsychopharmacol Biol Psychiatry 34, 1-4. Ebenbichler, C., Laimer, M., Kranebitter, M., Lechleitner, M., Patsch, J.R., Baumgartner, S., Edlinger, M., Hofer, A., Hummer, M., Rettenbacher, M.A., et al. (2005). The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study. Schizophr Res 75, 143-146. Elman, I., Borsook, D., and Lukas, S.E. (2006). Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 31, 2091-2120. Gropp, E., Shanabrough, M., Borok, E., Xu, A.W., Janoschek, R., Buch, T., Plum, L., Balthasar, N., Hampel, B., Waisman, A., et al. (2005). Agouti-related peptide-expressing neurons are mandatory for feeding. Nat Neurosci 8, 1289-1291. Gwinn, D.M., Shackelford, D.B., Egan, D.F., Mihaylova, M.M., Mery, A., Vasquez, D.S., Turk, B.E., and Shaw, R.J. (2008). AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30, 214-226. Hajra, B., Orakzai, B.A., Faryal, U., Hassan, M., Rasheed, S., and Wazir, S. (2016). Insulin Sensitivity To Trace Metals (Chromium, Manganese) In Type 2 Diabetic Patients And Non Diabetic Individuals. J Ayub Med Coll Abbottabad 28, 534-536. Halaas, J.L., Gajiwala, K.S., Maffei, M., Cohen, S.L., Chait, B.T., Rabinowitz, D., Lallone, R.L., Burley, S.K., and Friedman, J.M. (1995). Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269, 543-546. Handschin, C., and Spiegelman, B.M. (2006). Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 27, 728-735. Hardie, D.G., and Ashford, M.L. (2014). AMPK: regulating energy balance at the cellular and whole body levels. Physiology (Bethesda) 29, 99-107. Hardie, D.G., Scott, J.W., Pan, D.A., and Hudson, E.R. (2003). Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 546, 113-120. Hiroshima, Y., Yamamoto, T., Watanabe, M., Baba, Y., and Shinohara, Y. (2018). Effects of cold exposure on metabolites in brown adipose tissue of rats. Mol Genet Metab Rep 15, 36-42. Holder, S.D., and Wayhs, A. (2014). Schizophrenia. Am Fam Physician 90, 775-782. Hu, Y., Young, A.J., Ehli, E.A., Nowotny, D., Davies, P.S., Droke, E.A., Soundy, T.J., and Davies, G.E. (2014). Metformin and berberine prevent olanzapine-induced weight gain in rats. PLoS One 9, e93310. Huang, P.L. (2009). A comprehensive definition for metabolic syndrome. Dis Model Mech 2, 231-237. Jain, S.K., Patel, P., Rogier, K., and Jain, S.K. (2006). Trivalent chromium inhibits protein glycosylation and lipid peroxidation in high glucose-treated erythrocytes. Antioxid Redox Signal 8, 238-241. Jain, S.K., Rains, J.L., and Croad, J.L. (2007). Effect of chromium niacinate and chromium picolinate supplementation on lipid peroxidation, TNF-alpha, IL-6, CRP, glycated hemoglobin, triglycerides, and cholesterol levels in blood of streptozotocin-treated diabetic rats. Free Radic Biol Med 43, 1124-1131. Khoo, M.C., Oliveira, F.M., and Cheng, L. (2013). Understanding the metabolic syndrome: a modeling perspective. IEEE Rev Biomed Eng 6, 143-155. Kim, C.W., Kim, B.T., Park, K.H., Kim, K.M., Lee, D.J., Yang, S.W., and Joo, N.S. (2011). Effects of short-term chromium supplementation on insulin sensitivity and body composition in overweight children: randomized, double-blind, placebo-controlled study. J Nutr Biochem 22, 1030-1034. Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Duggan, L., Kissling, W., and Leucht, S. (2010). Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev, CD006654. Kroeze, W.K., Hufeisen, S.J., Popadak, B.A., Renock, S.M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H.Y., and Roth, B.L. (2003). H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28, 519-526. Lau, F.C., Bagchi, M., Sen, C.K., and Bagchi, D. (2008). Nutrigenomic basis of beneficial effects of chromium(III) on obesity and diabetes. Mol Cell Biochem 317, 1-10. Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., and Davis, J.M. (2009). A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166, 152-163. Li, P., Snyder, G.L., and Vanover, K.E. (2016). Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future. Curr Top Med Chem 16, 3385-3403. Lima, K.V., Lima, R.P., Goncalves, M.C., Faintuch, J., Morais, L.C., Asciutti, L.S., and Costa, M.J. (2014). High frequency of serum chromium deficiency and association of chromium with triglyceride and cholesterol concentrations in patients awaiting bariatric surgery. Obes Surg 24, 771-776. M, D.E.H., Schreurs, V., Vancampfort, D., and R, V.A.N.W. (2009). Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 8, 15-22. Ma, X.J., Maimaitirexiati, T.X., Zhang, R., Hu, G., and Luo, X. (2015). Effects of glucose and disorders in lipid metabolism on cytokine levels and cognitive impairment in the olanzapine-induced obesity rat model. Genet Mol Res 14, 11396-11402. Mackin, P., Watkinson, H.M., and Young, A.H. (2005). Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia 48, 215-221. Mamikutty, N., Thent, Z.C., Sapri, S.R., Sahruddin, N.N., Mohd Yusof, M.R., and Haji Suhaimi, F. (2014). The establishment of metabolic syndrome model by induction of fructose drinking water in male Wistar rats. Biomed Res Int 2014, 263897. Martin, K.A., Mani, M.V., and Mani, A. (2015). New targets to treat obesity and the metabolic syndrome. Eur J Pharmacol 763, 64-74. Martin, T.L., Alquier, T., Asakura, K., Furukawa, N., Preitner, F., and Kahn, B.B. (2006). Diet-induced obesity alters AMP kinase activity in hypothalamus and skeletal muscle. J Biol Chem 281, 18933-18941. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., and Turner, R.C. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419. Maury, E., and Brichard, S.M. (2010). Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 314, 1-16. McQuade, R.D., Stock, E., Marcus, R., Jody, D., Gharbia, N.A., Vanveggel, S., Archibald, D., and Carson, W.H. (2004). A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65 Suppl 18, 47-56. Newcomer, J.W. (2007). Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68 Suppl 1, 20-27. Organization, W.H. (2000). Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 894, i-xii, 1-253. Organization, W.H. (2018). OBESITY AND OVERWEIGHT. Posey, K.A., Clegg, D.J., Printz, R.L., Byun, J., Morton, G.J., Vivekanandan-Giri, A., Pennathur, S., Baskin, D.G., Heinecke, J.W., Woods, S.C., et al. (2009). Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet. Am J Physiol Endocrinol Metab 296, E1003-1012. Poulsen, L., Siersbaek, M., and Mandrup, S. (2012). PPARs: fatty acid sensors controlling metabolism. Semin Cell Dev Biol 23, 631-639. Ricardo-Gonzalez, R.R., Red Eagle, A., Odegaard, J.I., Jouihan, H., Morel, C.R., Heredia, J.E., Mukundan, L., Wu, D., Locksley, R.M., and Chawla, A. (2010). IL-4/STAT6 immune axis regulates peripheral nutrient metabolism and insulin sensitivity. Proc Natl Acad Sci U S A 107, 22617-22622. Richter, E.A., and Ruderman, N.B. (2009). AMPK and the biochemistry of exercise: implications for human health and disease. Biochem J 418, 261-275. Roerig, J.L., Steffen, K.J., and Mitchell, J.E. (2011). Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs 25, 1035-1059. Rojas, J., Arraiz, N., Aguirre, M., Velasco, M., and Bermudez, V. (2011). AMPK as Target for Intervention in Childhood and Adolescent Obesity. J Obes 2011, 252817. Roth, B.L., Sheffler, D.J., and Kroeze, W.K. (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3, 353-359. Rucker, D., Padwal, R., Li, S.K., Curioni, C., and Lau, D.C. (2007). Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335, 1194-1199. Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C.A., Kissling, W., Davis, J.M., and Leucht, S. (2010). Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123, 225-233. Rutter, G.A., Da Silva Xavier, G., and Leclerc, I. (2003). Roles of 5'-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochem J 375, 1-16. Scheen, A.J., and De Hert, M.A. (2007). Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 33, 169-175. Sim, A.T., and Hardie, D.G. (1988). The low activity of acetyl-CoA carboxylase in basal and glucagon-stimulated hepatocytes is due to phosphorylation by the AMP-activated protein kinase and not cyclic AMP-dependent protein kinase. FEBS Lett 233, 294-298. Stelzer, I., Zelzer, S., Raggam, R.B., Pruller, F., Truschnig-Wilders, M., Meinitzer, A., Schnedl, W.J., Horejsi, R., Moller, R., Weghuber, D., et al. (2012). Link between leptin and interleukin-6 levels in the initial phase of obesity related inflammation. Transl Res 159, 118-124. Suksomboon, N., Poolsup, N., and Yuwanakorn, A. (2014). Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. J Clin Pharm Ther 39, 292-306. Wang, Z.Q., Zhang, X.H., Russell, J.C., Hulver, M., and Cefalu, W.T. (2006). Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. J Nutr 136, 415-420. Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., and Ferrante, A.W., Jr. (2003). Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112, 1796-1808. Woods, S.C., and D'Alessio, D.A. (2008). Central control of body weight and appetite. J Clin Endocrinol Metab 93, S37-50. Ye, J. (2013). Mechanisms of insulin resistance in obesity. Front Med 7, 14-24. Zhao, P., Wang, J., Ma, H., Xiao, Y., He, L., Tong, C., Wang, Z., Zheng, Q., Dolence, E.K., Nair, S., et al. (2009). A newly synthetic chromium complex-chromium (D-phenylalanine)3 activates AMP-activated protein kinase and stimulates glucose transport. Biochem Pharmacol 77, 1002-1010.
摘要: 思覺失調症約占全世界人口1%的精神疾病。由於錐體外路徑症候群(EPS)副作用的發生率較低,因此第二代抗精神病藥物常作為思覺失調症患者的第一線治療藥物。然而,使用這類藥物經常伴隨的肥胖和胰島素相關的代謝紊亂,像是血脂異常和第二型糖尿病的產生,影響了這些藥物的臨床應用。微量元素在調節身體的正常代謝具有重要價值,因為它們與許多酵素及荷爾蒙之間具有相互作用。鉻是碳水化合物、蛋白質和脂肪正常代謝所需的一種微量元素。先前的一些研究表明,鉻能夠提高了胰島素的活性,而經由膳食補充鉻可以調節並改善葡萄糖代謝。鉻還能抑制食慾,增加熱量產生和維持體內衡定。因此本實驗目的是為了解olanzapine對大鼠體內鉻離子分佈的影響和鉻離子補充是否可以改善olanzapine誘導的肥胖雌性大鼠。在這研究中,利用Sprague-Dawley (SD) 雌性大鼠分為對照組和olanzapine組。實驗進行14天後將動物犧牲,取出血液,尿液,相關器官並進行分析。實驗結果表明, olanzapine與對照組相比體重顯著增加。動物的血糖,胰島素,脂質和發炎細胞激素瘦素和介白質素-6也呈上升趨勢。在AMPK訊號傳遞路徑中,olanzapine與對照組相比發現AMPK和ACC蛋白質磷酸化減少。在肝臟和白色脂肪組織中微量元素鉻含量也顯著低於對照組。我們還分析了鉻離子補充劑對olanzapine誘導代謝異常動物的影響。結果表明,補充鉻可顯著改善體重、血糖、胰島素、脂質、發炎性細胞激素和AMPK訊號傳遞路徑。我們的研究結果表明,olanzapine治療後體重明顯增加,並可能存在代謝症候群。補充鉻離子能有效改善olanzapine誘導肥胖代謝異常。
Schizophrenia is a mental illness that affects one percent of people worldwide. Due to their lower incidences of extrapyramidal symptoms (EPS) side effects, second-generation antipsychotics (SGAs) are the first line of treatment for those with schizophrenia. However, the accompanying obesity and insulin-related metabolic disorders including dyslipidemia, and type 2 diabetes hinder their clinical application. Trace elements are of great value in regulation of normal body metabolism, as they interact with many enzymes and hormones. Chromium (Cr) is one of trace elements required for the normal metabolism of carbohydrate, protein and fat. Previous research revealed that chromium raises the activity of insulin, and dietary supplementation with chromium has regulated improvements in glucose metabolism. Chromium also suppress the appetite and increase heat production energy and homeostasis. We aimed to identify empirical research on Cr distribution and Cr supplement may improve metabolic syndrome on olanzapine-induced obesity rats. Here, the experimental design Sprague-Dawley (SD) female rats were divided into groups of control and olanzapine group. These female rats were sacrificed 14 days after the experiment, and remove the blood, urine, related organs and analyze. The experimental results showed that olanzapine was significantly increased the body weight compared to the control. The blood glucose, insulin, lipids, and inflammatory cytokines leptin and IL-6 in olanzapine also showed an upward trend. Olanzapine decreased in AMPK and ACC compared with control in AMPK pathway. Analysis of trace elements, Cr had a significant decrease in olanzapine in the liver and white adipose tissue compared with control. We also analyzed the effect of Cr supplement on olanzapine induced metabolic disorders animal. The results showed that chromium supplementation significantly ameliorate in body weight, blood glucose, insulin, lipids, inflammatory cytokines and AMPK pathway. According to the above results, our findings showed that after the treatment of olanzapine, the body weight increased significantly, and there may be a metabolic syndrome. And chromium have been displayed for improving metabolic disorders on olanzapine-induced obesity in female rats.
URI: http://hdl.handle.net/11455/98522
文章公開時間: 2021-08-31
Appears in Collections:獸醫學系所

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.